Ligand Pharmaceuticals LGND Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxLiabilitiesNet.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's deferred tax assets?
- Ligand Pharmaceuticals (LGND) reported deferred tax assets of $22.61M in Q1 2026.
- How has Ligand Pharmaceuticals's deferred tax assets changed year-over-year?
- Ligand Pharmaceuticals's deferred tax assets decreased by 23.0% year-over-year, from $29.38M to $22.61M.
- What is the long-term trend for Ligand Pharmaceuticals's deferred tax assets?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's deferred tax assets has grown at a -11.0% compound annual growth rate (CAGR), from $64.6M to $36.02M.
- What does deferred tax assets mean?
- Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.